NEXGEL, Inc. (NASDAQ:NXGL) CEO Adam R. Levy Sells 4,000 Shares

NEXGEL, Inc. (NASDAQ:NXGL) CEO Adam R. Levy sold 4,000 shares of the stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $3.64, for a total transaction of $14,560.00. Following the completion of the transaction, the chief executive officer now directly owns 378,284 shares of the company’s stock, valued at approximately $1,376,953.76. The trade was a 1.05 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

NEXGEL Stock Down 0.0 %

NASDAQ NXGL opened at $3.54 on Thursday. The stock’s 50 day moving average is $3.86 and its 200 day moving average is $3.19. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.93 and a current ratio of 1.51. NEXGEL, Inc. has a twelve month low of $1.84 and a twelve month high of $5.10.

Institutional Trading of NEXGEL

An institutional investor recently raised its position in NEXGEL stock. Northeast Financial Group Inc. boosted its holdings in shares of NEXGEL, Inc. (NASDAQ:NXGL) by 168.8% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 31,848 shares of the company’s stock after acquiring an additional 20,000 shares during the period. Northeast Financial Group Inc. owned 0.50% of NEXGEL worth $82,000 at the end of the most recent reporting period. 2.21% of the stock is currently owned by institutional investors and hedge funds.

About NEXGEL

NEXGEL, Inc manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels. Its products are used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was formerly known as AquaMed Technologies, Inc and changed its name to NEXGEL, Inc in November 2019.